MetaVia to share latest research on DA-1726 for obesity and metabolic disorders at ObesityWeek 2025

MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), have been accepted for poster presentations at ObesityWeek 2025, taking place in-person and virtually November 4-7, 2025 in Atlanta, GA.

• Title:  Safety, Tolerability, and Pharmacokinetics of DA-1726, an Oxyntomodulin Analogue in a Phase 1 Study
• Presenting Author: Chris Fang, M.D., Consulting Chief Medical Officer of MetaVia
• Poster Number: P-209
• Session Date: Tuesday, November 4, 2025
• Session Time: 7:30-8:30 pm ET
• Session Location: Exhibit Hall A1

• Title:  DA-1726, an Oxyntomodulin Analogue: A Promising Therapy for Obesity and Related Metabolic Disorders
• Presenting Author: Tae-Hyoung Kim, M.S., Lead Research Scientist of Dong-A ST
• Poster Number: P-154
• Session Date: Tuesday, November 4, 2025
• Session Time: 7:30-8:30 pm ET
• Session Location: Exhibit Hall A1

A copy of the posters will be available on the Posters section of the MetaVia website after the presentations.